OrganoORGANO CORPORATION6368東証プライム機械FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥21 is left as operating profit. Revenue changed +8.8% from the prior year, operating profit +21.0%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 8.2% | 0.86× | 7.1% | 1.75× | 12.3% |
| 2023 | 8.9% | 0.90× | 7.9% | 1.86× | 14.8% |
| 2024 | 11.5% | 0.87× | 10.0% | 1.91× | 19.0% |
| 2025 | 14.8% | 0.87× | 12.8% | 1.76× | 22.6% |
| 2026 | 16.0% | 0.85× | 13.5% | 1.66× | 22.5% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 112,069 | 132,426 | 150,356 | 163,269 | 177,654 |
| Cost of revenue | 83,556 | 97,449 | 106,514 | 108,087 | 112,570 |
| Gross profit | 28,512 | 34,976 | 43,841 | 55,182 | 65,084 |
| SG&A | 17,662 | 19,763 | 21,297 | 24,061 | 27,435 |
| Operating income | 10,850 | 15,212 | 22,544 | 31,120 | 37,648 |
| Pretax income | 12,696 | 16,035 | 23,633 | 32,358 | 38,309 |
| Income tax | 3,470 | 4,270 | 6,298 | 8,171 | 9,908 |
| Net income attributable to owners | 9,210 | 11,730 | 17,310 | 24,150 | 28,401 |
| Operating margin | 9.7% | 11.5% | 15.0% | 19.1% | 21.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥20.2B | ¥15.6B | ¥17.6B | ¥16.8B | ¥31.1B |
| Total assets | ¥130.5B | ¥164.9B | ¥182.7B | ¥194.4B | ¥224.9B |
| Net assets | ¥76B | ¥86.4B | ¥102.1B | ¥121.2B | ¥143B |
| Share capital | ¥8.22B | ¥8.22B | ¥8.22B | ¥8.22B | ¥8.22B |
| Property, plant and equipment | ¥21B | ¥20.8B | ¥20.6B | ¥21.5B | ¥22.4B |
| Intangible assets excluding goodwill | ¥1.08B | ¥949M | ¥986M | ¥1.12B | ¥1.57B |
| Investment securities | ¥2.06B | ¥2.43B | ¥2.83B | ¥2.37B | ¥2.72B |
| Current assets | ¥102.9B | ¥136.8B | ¥153.5B | ¥164.4B | ¥192B |
| Current liabilities | ¥43.1B | ¥68.7B | ¥72.6B | ¥64.4B | ¥70.9B |
| Trade payables | ¥18.8B | ¥20.9B | ¥19.8B | ¥23.4B | ¥20B |
| Short-term borrowings | ¥9.93B | ¥29.1B | ¥34.1B | ¥18.9B | ¥28.4B |
| Long-term borrowings | ¥5.7B | ¥3.9B | ¥2.4B | ¥3.68B | ¥6B |
| Total liabilities | ¥54.5B | ¥78.5B | ¥80.6B | ¥73.2B | ¥81.9B |
| Non-controlling interests | ¥168M | ¥201M | ¥219M | ¥246M | — |
| Equity attributable to owners of parent | ¥74.6B | ¥84.1B | ¥98.1B | ¥116B | ¥136B |
| Retained earnings | ¥59.6B | ¥69B | ¥82.9B | ¥101B | ¥120.9B |
| Treasury stock | -¥734M | -¥613M | -¥518M | -¥746M | -¥642M |
EDINET (FSA Japan)
有価証券報告書-第81期(2025/04/01-2026/03/31)
EDINET (FSA Japan)
有価証券報告書-第80期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第79期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
有価証券報告書-第78期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
訂正有価証券報告書-第77期(令和3年4月1日-令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書-第76期(令和2年4月1日-令和3年3月31日)
Extracted from XBRL: 51 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.